Clinical Trial Update: The Efficacy and Safety of REX-001 to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating REX-001 for ischemic ulcers in patients with Critical Limb Ischemia (CLI) and diabetes was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Critical Limb Ischemia
• Diabetes Mellitus
• Peripheral Arterial Disease
• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Drugs mentioned

• REX-001

Snippet

Sponsor: Ixaka Ltd | Conditions: Peripheral Arterial Disease (PAD), Diabetes Mellitus (DM) | Phase 3 | Status: TERMINATED